Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration

Villate-Beitia, Ilia; Gallego, Idoia; Martı́nez, Gema; Zárate, Jon; López-Méndez, Tania B.; Soto-Sánchez, Cristina; Santos‐Vizcaíno, Edorta; Puras, Gustavo; Fernández, Eduardo; Pedraz, José Luís

doi:10.1016/j.ijpharm.2018.07.035

Cited by 30 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, dichloromethane is added to the aqueous phase and emulsified. After the niosomes are prepared, plasmid DNA is added inside niosome solutions to obtain nioplexes [ 38 ].…”

Section: Niosomes As New Drug Delivery Systemsmentioning

confidence: 99%

Niosomal Drug Delivery Systems for Ocular Disease—Recent Advances and Future Prospects

et al. 2020

View full text Add to dashboard Cite

The eye is a complex organ consisting of several protective barriers and particular defense mechanisms. Since this organ is exposed to various infections, genetic disorders, and visual impairments it is essential to provide necessary drugs through the appropriate delivery routes and vehicles. The topical route of administration, as the most commonly used approach, maybe inefficient due to low drug bioavailability. New generation safe, effective, and targeted drug delivery systems based on nanocarriers have the capability to circumvent limitations associated with the complex anatomy of the eye. Nanotechnology, through various nanoparticles like niosomes, liposomes, micelles, dendrimers, and different polymeric vesicles play an active role in ophthalmology and ocular drug delivery systems. Niosomes, which are nano-vesicles composed of non-ionic surfactants, are emerging nanocarriers in drug delivery applications due to their solution/storage stability and cost-effectiveness. Additionally, they are biocompatible, biodegradable, flexible in structure, and suitable for loading both hydrophobic and hydrophilic drugs. These characteristics make niosomes promising nanocarriers in the treatment of ocular diseases. Hereby, we review niosome based drug delivery approaches in ophthalmology starting with different preparation methods of niosomes, drug loading/release mechanisms, characterization techniques of niosome nanocarriers and eventually successful applications in the treatment of ocular disorders.

show abstract

“…Then, dichloromethane is added to the aqueous phase and emulsified. After the niosomes are prepared, plasmid DNA is added inside niosome solutions to obtain nioplexes [ 38 ].…”

Section: Niosomes As New Drug Delivery Systemsmentioning

confidence: 99%

Niosomal Drug Delivery Systems for Ocular Disease—Recent Advances and Future Prospects

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some non-ionic surfactants that have been used in niosomes designed for gene delivery applications include polyoxyethylene alkyl ether (Brij © [73]), polysorbates (Tween © [80]), sorbitan fatty acid esters (Span © [81]), or poloxamers [82]. The most relevant parameters of non-ionic surfactants to consider are the hydrophilic/lipophilic balance (HLB), which can be used as a "saving guide" parameter to select the appropriate surfactant [83], the critical packing parameter (CPP), which plays an important role in the vesicular-forming ability of niosomes [84], or the gel liquid transition temperature (T C ), which has a relevant impact on the drug entrapped efficiency [85]. Among the cationic lipids, some of the most employed in the elaboration of niosomes for gene delivery purposes include 2,3-di(tetradecyloxy)propan-1-amine hydrochloride salt [86] [51], to name just a few.…”

Section: Components On Niosome Formulationsmentioning

confidence: 99%

“…Typically, it is accepted that ζ values of nanoparticles over 20 mV (either negative or positive) prevent aggregation by electrostatic repulsion [102]. When nioplexes are elaborated, positively charged cationic groups of niosomes are partially neutralized by the negatively charged phosphate groups of genetic material, resulting in a decrease of superficial charge which will depend on the cationic lipid/genetic material ratio [83]. Normally, nioplexes are elaborated at positive cationic lipid/genetic material ratios to enhance the cellular uptake of such nioplexes by interaction with the negatively charged cell membranes.…”

Section: Physicochemical Characterization Of Niosome Nanoparticlesmentioning

confidence: 99%

“…In fact, in 2018, three niosome formulations that only differed in the polysorbate non-ionic tensioactive were elaborated by the solvent evaporation technique. The three niosome vesicles shared the same commercially available cationic lipid 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), the same "helper" lipid squalene, and had polysorbate 20, polysorbate 80 or polysorbate 85 as non-ionic tensioactives [83]. Polysorbate 20 has the highest HLB value (16.7) and upon the incorporation of reported pCMSEGFP plasmid on the surface of corresponding niosomes to obtain nioplexes at a 2/1 ratio of cationic lipid/DNA, RPE cultured cells were successfully transfected without signs of toxicity.…”

Section: Niosomes For Gene Delivery To the Retinamentioning

confidence: 99%

See 1 more Smart Citation

Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues

et al. 2020

Self Cite

View full text Add to dashboard Cite

Non-viral vectors have emerged as a promising alternative to viral gene delivery systems due to their safer profile. Among non-viral vectors, recently, niosomes have shown favorable properties for gene delivery, including low toxicity, high stability, and easy production. The three main components of niosome formulations include a cationic lipid that is responsible for the electrostatic interactions with the negatively charged genetic material, a non-ionic surfactant that enhances the long-term stability of the niosome, and a helper component that can be added to improve its physicochemical properties and biological performance. This review is aimed at providing recent information about niosome-based non-viral vectors for gene delivery purposes. Specially, we will discuss the composition, preparation methods, physicochemical properties, and biological evaluation of niosomes and corresponding nioplexes that result from the addition of the genetic material onto their cationic surface. Next, we will focus on the in situ application of such niosomes to deliver the genetic material into immune-privileged tissues such as the brain cortex and the retina. Finally, as future perspectives, non-invasive administration routes and different targeting strategies will be discussed.

show abstract

“…Tween 80 and Tween 20 have a similar branched PEG structure linking to an unsaturated C17 and a saturated C11 tail, respectively [31][32][33]. Importantly, both Tween 80 and 20 are biocompatible, have been clinically used in injectable formulations, can stabilize lipid bilayers in serum, and enhance gene delivery efficiency [34][35][36]. Therefore, we employed Tween 80 and 20 to replace a widely used PEG attaching to two stearoyl tails (PEG-DSPE) and subsequently studied the size, charge, stability and DNA encapsulation efficiency of the resulting LNPs.…”

Section: Introductionmentioning

confidence: 99%

The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles

et al. 2020

View full text Add to dashboard Cite

Targeted delivery of nucleic acids to lymph nodes is critical for the development of effective vaccines and immunotherapies. However, it remains challenging to achieve selective lymph node delivery. Current gene delivery systems target mainly to the liver and typically exhibit off-target transfection at various tissues. Here we report novel lipid nanoparticles (LNPs) that can deliver plasmid DNA (pDNA) to a draining lymph node, thereby significantly enhancing transfection at this target organ, and substantially reducing gene expression at the intramuscular injection site (muscle). In particular, we discovered that LNPs stabilized by 3% Tween 20, a surfactant with a branched poly(ethylene glycol) (PEG) chain linking to a short lipid tail, achieved highly specific transfection at the lymph node. This was in contrast to conventional LNPs stabilized with a linear PEG chain and two saturated lipid tails (PEG-DSPE) that predominately transfected at the injection site (muscle). Interestingly, replacing Tween 20 with Tween 80, which has a longer unsaturated lipid tail, led to a much lower transfection efficiency. Our work demonstrates the importance of PEGylation in selective organ targeting of nanoparticles, provides new insights into the structure–property relationship of LNPs, and offers a novel, simple, and practical PEGylation technology to prepare the next generation of safe and effective vaccines against viruses or tumours.

show abstract

Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration

Cited by 30 publications

References 38 publications

Niosomal Drug Delivery Systems for Ocular Disease—Recent Advances and Future Prospects

Niosomal Drug Delivery Systems for Ocular Disease—Recent Advances and Future Prospects

Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues

The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles

Contact Info

Product

Resources

About